Browsing Tag
BVF Partners
7 posts
Superluminal lands $60m Series B to take genetic obesity drug into human trials
Superluminal Medicines has secured an oversubscribed $60 million Series B to move a selective small-molecule MC4R agonist into Phase 1, entering an obesity niche where Rhythm Pharmaceuticals already generates more than $70 million a quarter.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.
Could one hair loss antibody make Absci’s AI drug platform harder to ignore?
Absci’s ABS-201 data and $100 million raise sharpen ABSI’s AI biologics story across androgenetic alopecia, endometriosis and platform validation.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Pyxis Oncology raises $152m in Series B round for cancer therapies
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by…
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…
Protagonist Therapeutics secures $22m to advance IBD treatment
Protagonist Therapeutics, a clinical-stage biopharmaceutical company specializing in the discovery and development of novel peptide-based drugs, has successfully…